EMA Authorised: Ontozry (cenobamate) — Angelini Pharma S.p.A

View source ↗

Summary

EMA has authorised Ontozry (cenobamate) for epilepsy, with Angelini Pharma S.p.A as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Ontozry (cenobamate)

Snippet

Status: Authorised. Therapeutic area: Epilepsy. MAH: Angelini Pharma S.p.A. Decision date: 19/06/2026